Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Novo Nordisk A/S Key Target Audience Market Players Investors End-users Government Authorities Consulting and Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In January 2023, Semaglutide (Wegovy- Novo Nordisk) has been licensed by the US Food and Drug Administration for the treatment of obesity in pediatric patients aged 12 and above
Pregnancy and Nursing: According to SkinnyRx, GLP-1 medications should not be used during pregnancy or breastfeeding
Both approaches offer distinct advantages, and the right choice depends on your medical complexity, budget, and personal preferences
In most of the acute infusion studies conducted in healthy adults, BP was unchanged
Contact your GP or diabetes care team for assessment
Semaglutide is an FDA-approved medication originally developed to treat type 2 diabetes
US$ 23.80
US$ 21.12
US$ 28.92
US$ 28.82
US$ 24.29
